Journal of Practical Hepatology ›› 2024, Vol. 27 ›› Issue (2): 263-266.doi: 10.3969/j.issn.1672-5069.2024.02.026

• Hepatoma • Previous Articles     Next Articles

Venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with primary liver cancer

Yang Fan, Yang Jun, Pu Zhongjian, et al.   

  1. Department of Oncology, Hai'an Traditional Chinese Medicine Hospital, Nantong 226600, Jiangsu Province, China
  • Received:2023-09-26 Online:2024-02-10 Published:2024-03-08

Abstract: Objective This clinical trial was conducted to investigate the efficacy of venous administration of vitamin B6 sodium cantharidate after transhepatic arterial chemoembolization (TACE) in the treatment of patients with primary liver cancer (PLC). Methods 84 patients with PLC were encountered in our hospital between January 2019 and January 2022, and 42 patients in the control received TACE and another 42 patients in the observation were treated by TACE followed by venous administration of vitamin B6 sodium cantharidate for three weeks. All patients in the two groups were followed-up for one year. Serum alpha-fetoprotein (AFP) levels were detected by chemical fluorescence assay, serum carbohydrate antigen 125 (CA125) levels were detected by chemiluminescence immunoassay, and serum carbohydrate antigen 199 (CA199) levels were detected by direct chemiluminescence assay. Serum homocysteine (Hcy) levels were detected by enzymatic method, serum nitric oxide (NO) levels were assayed by nitrate reduction method, and serum endothelin (ET-1) levels were determined by enhanced chemiluminescence immunoassay. Results The CR, PR, SD and PD in the observation were 7.1%, 42.9%, 38.1% (P<0.05) and 4.8%, while those in the control were 7.1%, 40.5%, 19.1% and 26.2%, with the SD significantly different between the two groups; after treatment, serum AFP, CA125 and CA199 levels in the observation group were (540.4±87.1)μg/L, (28.1±9.1)kU/L and (18.0±4.8)kU/L, all significantly lower than in the control; serum Hcy and ET-1 levels were (14.1±3.6)μmol/L and (66.1±10.3)ng/L, both much lower than [(18.4±4.3)μmol/L and (80.2±12.1)ng/L, respectively, P<0.05] in the control; the incidence of gastrointestinal reaction in the observation was 16.7%, much lower than 40.5%(P<0.05) in the control; there was no significant difference as respect to the one-year survival in the two groups (84.2% vs.76.9%, P>0.05). Conclusion The venous administration of vitamin B6 sodium cantharidate after TACE in the treatment of patients with PLC could ameliorate gastrointestinal reactions and improve the vascular endothelial functions.

Key words: Hepatoma, Transhepatic arterial chemoembolization, Vitamin B6 sodium cantharidate, Therapy